Physician Law Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Physician Law Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Acrongenomics, Inc.
Nano-JETA real time PCR compared with gold standard PCR
June 15th, 2005
Currently, molecular diagnostics market needs fast, personalized diagnosis, easy to handle methods, decreased cost and fast therapy decision without compromise in accuracy and reliability. Once these needs are covered a clear increase in growth rate of molecular diagnostics is expected. Polymerase chain reaction (PCR) applications in particular will reveal double-digit growth having the biggest share since PCR remains the workhorse for molecular genetic analysis. Acrongenomics, Inc., (AGNM) is currently conducting a clinical comparison study of its Nano-JETA Real Time PCR against the "gold standard", the common Real Time PCR technology, via the...
Source: Physician Law Weekly (2005-06-15)
|
